Nirsevimab in Chile’s First National RSV Campaign: 76% Reduction in RSV Hospitalisations and 85% Fewer ICU Admissions in Infants
Posted inInfectious Diseases news Pediatrics Public Health Respiratory

Nirsevimab in Chile’s First National RSV Campaign: 76% Reduction in RSV Hospitalisations and 85% Fewer ICU Admissions in Infants

A nationwide retrospective study from Chile finds that a universal nirsevimab immunisation strategy in 2024 reduced RSV-related lower respiratory tract infection hospitalisations by 76% and ICU admissions by 85%, with an NNT of 35 to prevent one RSV LRTI admission.
Real-world data suggest nirsevimab reduces RSV test-positivity up to 12 months but not beyond — cautious interpretation required
Posted inInfectious Diseases news Pediatrics Respiratory

Real-world data suggest nirsevimab reduces RSV test-positivity up to 12 months but not beyond — cautious interpretation required

A multicentre retrospective TriNetX analysis found reduced odds of RSV test-positivity for infants receiving nirsevimab when last dose was within 6–11 months before testing; protection was strongest within 6 months and not evident beyond 12 months. Methodological limits temper causal inference.
Cardiovascular and Respiratory Responses During Graded Exercise in Adolescents After Sport-Related Concussion: A Synthesis of Current Evidence
Posted inCardiology Clinical Updates news Rehabilitation Medicine Respiratory

Cardiovascular and Respiratory Responses During Graded Exercise in Adolescents After Sport-Related Concussion: A Synthesis of Current Evidence

Exploring altered cardiopulmonary dynamics and exercise intolerance in adolescents post-sport-related concussion reveals attenuated cardiovascular responses independent of aerobic deconditioning, highlighting autonomic dysregulation as a key mechanism.
Brensocatib Shows Imaging Signals of Structural Benefit in Non‑CF Bronchiectasis: CT Substudy from ASPEN Suggests Reduced Mucus Plugging and Modest Airway Change
Posted innews Respiratory

Brensocatib Shows Imaging Signals of Structural Benefit in Non‑CF Bronchiectasis: CT Substudy from ASPEN Suggests Reduced Mucus Plugging and Modest Airway Change

A 100‑patient CT substudy from the ASPEN program found that brensocatib, especially the 25‑mg dose, reduced mucus plugging and increased healthy parenchyma at 52 weeks, providing preliminary imaging evidence that it may modify disease biology in noncystic fibrosis bronchiectasis.
Evaluating the Cost-Effectiveness of Early In-Bed Cycling Plus Routine Physiotherapy in Mechanically Ventilated ICU Patients: Insights from the CYCLE Trial
Posted inCritical Care news Rehabilitation Medicine Respiratory

Evaluating the Cost-Effectiveness of Early In-Bed Cycling Plus Routine Physiotherapy in Mechanically Ventilated ICU Patients: Insights from the CYCLE Trial

This economic evaluation from the CYCLE randomized trial found no significant cost or quality-adjusted life-year benefit by adding early in-bed cycling to usual physiotherapy for ICU patients on mechanical ventilation, underscoring a need for further research to clarify its value.
Evaluating Portable HEPA Purifiers to Reduce Respiratory Viral Exposure in Elementary Schools: Insights from a Randomized Clinical Trial Secondary Analysis
Posted innews Pediatrics Public Health Respiratory

Evaluating Portable HEPA Purifiers to Reduce Respiratory Viral Exposure in Elementary Schools: Insights from a Randomized Clinical Trial Secondary Analysis

A secondary analysis of a cluster-randomized trial found that portable HEPA purifiers modestly reduced viral diversity but did not significantly lower high respiratory viral exposure in elementary school classrooms, suggesting multi-faceted interventions are needed to protect children in schools.